HDAC9 and primary cutaneous T-cell non-Hodgkin lymphoma: Based on the anti-tumor effects of DOT1L inhibitors in MLL-rearranged leukemia and thymic lymphoma, we also investigated whether DOT1L inhibitor treatment alone or in collaboration with HDAC inhibitors reduces viability of CTCL cells.